MIR361: A Non-Coding RNA Molecule as A Potential Drug Target (G494323)

MIR361: A Non-Coding RNA Molecule as A Potential Drug Target

MicroRNA (miRNA) 361 is a non-coding RNA molecule that plays a crucial role in regulating gene expression in various organisms, including humans. It is composed of 20 amino acid residues and has a unique structure that consists of a stem-loop and a terminal trail. MIR361 is expressed in various tissues of the body and is involved in various cellular processes, including cell growth, apoptosis, and inflammation.

Recent studies have identified MIR361 as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its unique structure and various functions make it an attractive target for small molecules, including anti-cancer drugs, anti-inflammatory drugs, and neurotransmitters.

One of the reasons why MIR361 has been identified as a potential drug target is its involvement in cancer development. MIR361 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in cancer development. It has been shown to inhibit the G1/S transition, which is the stage of cell growth where the cell prepares for cell division. This inhibition of the G1/S transition can lead to the cell remaining in the G1 phase for a longer period, leading to the accumulation of genetic mutations that can lead to cancer.

Another reason why MIR361 has been identified as a potential drug target is its involvement in neurodegenerative diseases. MIR361 has been shown to be involved in the regulation of neurotransmitter synthesis and release, which is critical for maintaining the integrity of the nervous system. It has been shown to play a role in the regulation of dopamine release and has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

MIR361 has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and has been shown to be involved in the development of inflammatory diseases, including rheumatoid arthritis and asthma.

In addition to its involvement in cancer, neurodegenerative diseases, and inflammation, MIR361 has also been shown to be involved in other cellular processes that are important for human health. For example, it has been shown to play a role in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. It has also been shown to play a role in the regulation of cell migration, which is important for the development and maintenance of tissues and organs.

Given its unique structure and various functions, MIR361 has been shown to be a promising target for small molecules. Studies have shown that MIR361 can be effectively targeted with small molecules, including inhibitors of the miRNA pathway, which are drugs that can interact with MIR361 and prevent it from interacting with its downstream targets. These drugs have the potential to be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, MIR361 is a non-coding RNA molecule that plays a crucial role in regulating gene expression in various organisms. Its unique structure and various functions make it an attractive target for small molecules, including anti-cancer drugs, anti-inflammatory drugs, and neurotransmitters. Further studies are needed to fully understand the role of MIR361 in various cellular processes and to identify potential drugs that can target it effectively.

Protein Name: MicroRNA 361

The "MIR361 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR361 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677 | MIR3678 | MIR3679 | MIR3680-1 | MIR3680-2 | MIR3681 | MIR3681HG | MIR3682 | MIR3683 | MIR3685 | MIR3686 | MIR3687 | MIR3688-1 | MIR3688-2 | MIR3689A | MIR3689B | MIR3689C | MIR3689D1 | MIR3689D2 | MIR3689F | MIR369 | MIR3690 | MIR3691 | MIR3692 | MIR370 | MIR3713 | MIR3714 | MIR371A | MIR371B | MIR372 | MIR373 | MIR374A | MIR374B | MIR374C | MIR375 | MIR376A1 | MIR376A2 | MIR376B | MIR376C | MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384